Terms: = Colorectal cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
295 results:
1. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.
Yu H; Liu Q; Wu K; Tang S
Clin Exp Med; 2024 Jul; 24(1):143. PubMed ID: 38960935
[TBL] [Abstract] [Full Text] [Related]
2. Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.
Zhao R; Fan R; Pan Y; Han Y; Wang Y; Chen W
BMC Nephrol; 2024 May; 25(1):170. PubMed ID: 38762494
[TBL] [Abstract] [Full Text] [Related]
3. Anti-vegfr2-Interferon α Promotes the Infiltration of CD8+ T Cells in colorectal cancer by Upregulating the Expression of CCL5.
Huang L; Gao R; Nan L; Qi J; Yang S; Shao S; Xie J; Pan M; Qiu T; Zhang J
J Immunother; 2024 Jul-Aug 01; 47(6):195-204. PubMed ID: 38654631
[TBL] [Abstract] [Full Text] [Related]
4. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract] [Full Text] [Related]
5. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
6. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract] [Full Text] [Related]
7. Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following vegfr-2 and PD-1 blockade in a colon cancer model.
Xu X; Ma M; Ye K; Zhang D; Chen X; Wu J; Mo X; Xiao Z; Shi C; Luo L
J Transl Med; 2024 Feb; 22(1):198. PubMed ID: 38395884
[TBL] [Abstract] [Full Text] [Related]
8. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating vegfr2 signal pathway in colorectal cancer.
Wang S; Yang J; Kuang X; Li H; Du H; Wu Y; Xu F; Liu B
J Ethnopharmacol; 2024 May; 326():117913. PubMed ID: 38360380
[TBL] [Abstract] [Full Text] [Related]
9. Effects of total coumarins from
Liu Y; Cheng DH; Su ZY; Lv JH; Wang L; Deng YY; Li L
Pharm Biol; 2024 Dec; 62(1):153-161. PubMed ID: 38347502
[TBL] [Abstract] [Full Text] [Related]
10. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
12. Antitumor activity of the new tyrphostin briva against BRAF
Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B
Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738
[TBL] [Abstract] [Full Text] [Related]
13. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of colorectal cancer.
Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
[TBL] [Abstract] [Full Text] [Related]
14. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract] [Full Text] [Related]
16. Sequential-delivery nanocomplex for combined anti-angiogenesis and gene therapy against colorectal cancer.
Jia F; Li Y; Gao Y; Wang X; Lu J; Cui X; Pan Z; Xu C; Deng X; Wu Y
Int J Pharm; 2023 Apr; 637():122850. PubMed ID: 36990169
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of Fruquintinib in the Continuum of Care of Patients with colorectal cancer.
Lavacchi D; Roviello G; Guidolin A; Romano S; Venturini J; Caliman E; Vannini A; Giommoni E; Pellegrini E; Brugia M; Pillozzi S; Antonuzzo L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982913
[TBL] [Abstract] [Full Text] [Related]
18. A phase I dose-escalation study of SYHA1813, a vegfr and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
Kang Z; Li S; Lin Y; Li Y; Mao Y; Zhang J; Lei T; Wang H; Su Y; Yang Y; Qiu J; Li W
Invest New Drugs; 2023 Apr; 41(2):296-305. PubMed ID: 36884148
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
20. The association of blood ctDNA levels to mutations of marker genes in colorectal cancer.
Bai F; Du Q; Zou Q; Xu L; Dong W; Lv X; Han X; Zhou H; Zhang C; Lu T
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1782. PubMed ID: 36746394
[TBL] [Abstract] [Full Text] [Related]
[Next]
